Cash Flow Statement

Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mangoceuticals (MGRX) Long-Term Debt Issuances (2024)

Mangoceuticals' Long-Term Debt Issuances history spans 1 years, with the latest figure at $100000.0 for Q2 2024.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $100000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $187500.0, a N/A change, with the full-year FY2022 number at $89200.0, changed N/A from a year prior.
Long-Term Debt Issuances hit $100000.0 in Q2 2024 for Mangoceuticals, up from $87500.0 in the prior quarter.
Over the last five years, Long-Term Debt Issuances for MGRX hit a ceiling of $100000.0 in Q2 2024 and a floor of $87500.0 in Q1 2024.